Patricia Villagrasa

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer”.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

The Lancet Oncology(2020)10.1016/s1470-2045(20)30450-2

N/A

0.650DataRank · unranked

75 citations

Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci +34 more

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

ESMO Open(2024)10.1016/j.esmoop.2024.102388

N/A

0.442DataRank · unranked

18 citations

Tomás Pascual, Fara Brasó‐Maristany, Laia Paré, Olga Martínez‐Sáez, Javier Cortés +15 more

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Annals of Oncology(2024)10.1016/j.annonc.2024.10.012

N/A

0DataRank · unranked

31 citations

S.R. Stecklein, Oleg Gluz, Guillermo Villacampa, Marı́a del Monte-Millán, Ulrike Nitz +42 more

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf162

N/A

0DataRank · unranked

1 citations

Miguel Martín, Guillermo Villacampa, Marı́a del Monte-Millán, Rachel Yoder, Harsh B. Pathak +23 more